Physician profile
John Mongan
NPI 1134235765
$2,477.02
in general payments reported to CMS, 2019-2025
42 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $211 · 2021: $259 · 2022: $296 · 2023: $397 · 2024: $405 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.92 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $283.33 | 2019-2024 | Opdivo |
| Abbvie INC. | $193.09 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.00 | 2024-2025 | Ninlaro, Iclusig |
| Janssen Biotech, INC. | $114.18 | 2019-2024 | Darzalex, Imbruvica |
| Pfizer INC. | $106.77 | 2019-2025 | |
| Incyte Corporation | $99.75 | 2019-2025 | Jakafi |
| Astellas Pharma US INC | $96.89 | 2019-2023 | Xospata, Padcev |
| Emd Serono, INC. | $96.79 | 2021-2024 | Bavencio |
| Novartis Pharmaceuticals Corporation | $94.57 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $88.04 | 2019-2023 | Imbruvica |
| Exelixis INC. | $83.67 | 2019-2025 | Cabometyx |
| Epizyme, INC. | $77.72 | 2020-2022 | |
| Array Biopharma INC | $72.87 | 2021-2025 | Mektovi, Lorbrena, Braftovi |
| Pharmacosmos Therapeutics INC. | $67.18 | 2022-2024 | Monoferric |
| Glaxosmithkline, LLC. | $61.74 | 2020-2025 | Jemperli |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mongan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.